ERYTECH Pharma S.A. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported revenue was EUR 25.3 million compared to EUR 2.27 million a year ago. Net loss was EUR 1.02 million compared to EUR 27.95 million a year ago.

Basic loss per share from continuing operations was EUR 0.03 compared to EUR 1.22 a year ago. Diluted loss per share from continuing operations was EUR 0.03 compared to EUR 1.22 a year ago.